ReviewPituitary2016
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.
Review in Pituitary, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- Assessment of nurses' knowledge and awareness of acromegaly in a high-volume tertiary center: a cross-sectional study.Pituitary · 2026Article
- Article
- Diagnostic and prognostic value of myocardial work indices in evaluating cardiac function damage in active acromegaly patients.Endocrine connections · 2026Article
- More than just a polyp: Hidden acromegaly behind a giant colonic mass.SAGE open medical case reports · 2026Article
- Adherence, duration and healthcare costs in a real-world population of patients with acromegaly.Journal of comparative effectiveness research · 2025Article
- Dosing patterns, healthcare resource utilization and costs among acromegaly patients who consistently use lanreotide and injectable octreotide.Journal of comparative effectiveness research · 2025Observational
- Metabolic Factors Related to Interpersonal Dysfunction in Acromegaly: A Nationwide Cross-Sectional Study in China.CNS neuroscience & therapeutics · 2025Article
- Gross total resection in low-grade and pretreated high-grade invasive growth hormone pituitary adenomas promises favorable outcomes.Discover oncology · 2025Article
- Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Risk in Acromegaly Indicates Persistence of Cardiac Risks Despite Biochemical Disease Control.Journal of clinical medicine · 2025Article
- Oral Health and Quality of Life in Acromegaly: A Questionnaire-Based Study.Dentistry journal · 2025Article
- Cardiac structure and function recovery in acromegaly after treatment: insights from cardiac magnetic resonance imaging.Frontiers in endocrinology · 2025Article
- Ends of the spectrum best practices for early detection and multidisciplinary management of acromegaly.Journal of neuro-oncology · 2025Review
- Patient perspectives on acromegaly disease burden: insights from a community meeting.Frontiers in endocrinology · 2025Article
- Knowledge and attitudes of primary care physicians regarding acromegaly: a survey study with multinational participation.BMC primary care · 2024Article
- Acromegaly and COVID-19, lessons, and new opportunities.Pituitary · 2024Article
- Biochemical Control in a Colombian Cohort of Patients With Acromegaly: A 12-Month Follow-Up Study (2017-2023).Cureus · 2024Article
- Prevalence of Neoplasms in Patients with Acromegaly-A Single-Center Polish Study.Journal of clinical medicine · 2024Article
- Acromegaly in Speckle Tracking Echocardiography-A New Cardiac Hypertrophy Phenotype? Case Report and Review.Life (Basel, Switzerland) · 2024Review
- Regression of biventricular hypertrophy in acromegalic cardiomyopathy following management of excessive growth hormone secretion.Oxford medical case reports · 2024Article
- Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcromegaly is a rare, insidious disease resulting from the overproduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), and is associated with a range of comorbidities. The extent of associated complications and mortality risk is related to length of exposure to the excess GH and IGF-1, thus early diagnosis and treatment is imperative. Unfortunately, acromegaly is often diagnosed late, when patients already have a wide range of comorbidities. The presence of comorbid conditions contributes significantly to patient morbidity/mortality and impaired quality of life.
methodsWe conducted a retrospective literature review for information relating to the diagnosis of acromegaly, and its associated comorbidities using PubMed. The main aim of this review is to highlight the issues of comorbidities in acromegaly, and to reinforce the importance of early diagnosis and treatment. FINDINGS AND
conclusionsSuccessful management of acromegaly goes beyond treating the disease itself, since many patients are diagnosed late in disease evolution, they present with a range of comorbid conditions, such as cardiovascular disease, diabetes, hypertension, and sleep apnea. It is important that patients are screened carefully at diagnosis (and thereafter), for common associated complications, and that biochemical control does not become the only treatment goal. Mortality and morbidities in acromegaly can be reduced successfully if patients are treated using a multimodal approach with comprehensive comorbidity management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.